Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)
Open Posted
- Opportunity number
- PAR-28-056
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Up to $600,000
Opportunity facts
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Category
-
- Health
- Eligible applicants
-
- Public or Indian Housing Auth.
- State Governments
- Tribal Organizations (Not Federally Recognized)
- For Profit Organizations
- Higher Education Inst. (Private)
- Higher Education Inst. (Public)
- Tribal Governments (Federally Recognized)
- Independent School Districts
- Non-501(c)(3) Nonprofits
- City/Township Governments
- Other
- Special District Governments
- County Governments
- Small Businesses
- 501(c)(3) Nonprofits
- Points of contact
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Cancer Institute seeks cooperative agreement applications for the Pancreatic Cancer Detection Consortium Research Units to fund multidisciplinary teams conducting research on early detection of pancreatic ductal adenocarcinoma and characterization of precursor lesions, with a hard deadline of November 5, 2029.
Eligible applicants include higher education institutions (public and private), 501(c)(3) and non-501(c)(3) nonprofits, for-profit organizations, state and local governments, tribal organizations (federally and non-federally recognized), special district governments, school districts, housing authorities, faith-based and community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions. Non-domestic entities and foreign components are not eligible.
Individual awards carry a maximum of $600,000 in direct costs per year for a five-year project period. Applicants must allocate $100,000 annually in direct costs (years 2–5) for trans-PCDC collaborative studies and budget travel for two annual Steering Committee meetings. The Contact PD/PI and all other PDs/PIs must commit a minimum of 1.2 person-months per year. Applications are due quarterly: February 5, June 5, October 5, and specific dates in 2027–2029, with earliest start dates approximately four months after each due date.
Research Units must identify and test biomarkers in bodily fluids for PDAC early detection; develop molecular and imaging-based markers for pancreatic cysts to predict progression; create screening approaches for high-risk populations; apply machine learning and computational methods to biomarker discovery and validation; and conduct biomarker validation studies. Each unit must collect longitudinal biospecimens for the PCDC biorepository and participate in collaborative activities with other PCDC units, sharing data, biospecimens, and resources. Applications must include specific aims with quantitative milestones, a detailed research strategy addressing overview, approaches, study design, accomplishments, collaborative responsibilities, and annual milestones, institutional support letters, collaborator access documentation, a Data Management and Sharing Plan, and human subjects research documentation if applicable.
The funding is assigned to CFDA 93.393 (Cancer Cause and Prevention Research) and 93.394 (Cancer Detection and Diagnosis Research).
Synopsis
Through this Notice of Funding Opportunity (NOFO), NCI solicits applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the NCI's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma (PDAC). The PCDC will support research for the development and testing of new molecular and imaging biomarkers for detecting PDAC early and for identifying patients at high risk of PDAC (because of genetic factors, family history and/or the presence of precursor lesions) who could be candidates for early intervention. The PCDC-RUs will consist of multi-disciplinary teams and will undertake studies to: identify and test biomarkers measurable in bodily fluids for early detection of PDAC and/or its precursor lesions; develop molecular- and/or imaging-based markers of pancreatic cysts and determine which lesions are likely to progress to cancer; develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC; use machine learning and computational approaches towards biomarker discovery and/or validation; and conduct biomarker validation studies. The PCDC-RUs will also collect longitudinal biospecimens for building a biorepository. Each PCDC-RU is expected to participate in collaborative activities with other PCDC-RUs and share ideas, biospecimens, and data within the Consortium.
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Files
| File | Type | Posted |
|---|---|---|
| PKG00294252.pdf | ||
| PAR-28-056-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity